Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA3 | P34903 | 15/20 | 0.72 |
| ▸ | GABRG2 | P18507 | 12/20 | 0.72 |
| ▸ | GABRB3 | P28472 | 12/20 | 0.72 |
| ▸ | GABRA2 | P47869 | 11/20 | 0.72 |
| ▸ | GABRA1 | P14867 | 11/20 | 0.72 |
| ▸ | GABRA5 | P31644 | 10/20 | 0.72 |
| ▸ | GABRB2 | P47870 | 7/20 | 0.72 |
| ▸ | GABRP | O00591 | 2/20 | 0.48 |
| ▸ | GABRD | O14764 | 2/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.48 |
| ▸ | GABRE | P78334 | 2/20 | 0.48 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.48 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.48 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.48 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.48 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.48 |
| ▸ | ALB | P02768 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7724596 | 0.87 | GABRA3 (0.63) | GABRA3GABRG2GABRB3GABRA2GABRA1 | |
| SCHEMBL2845678 | 0.86 | GABRA3 (0.74) | GABRA3GABRG2GABRB3GABRA2GABRA1 | |
| SCHEMBL29588960 | 0.84 | GABRA1 (1.00) | GABRA3GABRG2GABRB3GABRA2GABRA1 | |
| SCHEMBL2871536 | 0.84 | GABRA1 (1.00) | GABRA3GABRG2GABRB3GABRA2GABRA1 | |
| SCHEMBL20369049 | 0.83 | GABRA1 (0.70) | GABRA3GABRG2GABRB3GABRA2GABRA1 | |
| SCHEMBL13352287 | 0.83 | GABRA1 (0.51) | GABRA3GABRG2GABRB3GABRA2GABRA1 | |
| SCHEMBL16922124 | 0.83 | GABRA1 (0.70) | GABRA3GABRG2GABRB3GABRA2GABRA1 | |
| SCHEMBL6308282 | 0.82 | GABRA1 (0.66) | GABRA3GABRG2GABRB3GABRA2GABRA1 | |
| SCHEMBL7722307 | 0.82 | GABRA1 (1.00) | GABRA3GABRG2GABRB3GABRA2GABRA1 | |
| SCHEMBL31696028 | 0.82 | GABRA1 (0.79) | GABRA3GABRG2GABRB3GABRA2GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE47475-E1 | Selective agents for pain suppression | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-RE47475-E1 | Selective agents for pain suppression | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-8835424-B2 | Selective agents for pain suppression | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835424-B2 | Selective agents for pain suppression | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835424-B2 | Selective agents for pain suppression | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-20100317619-A1 | Selective Agents for Pain Suppression | COOK JAMES | 2010-12-16 | — | — | US | disclosed |
| US-20100317619-A1 | Selective Agents for Pain Suppression | COOK JAMES | 2010-12-16 | — | — | US | disclosed |
| US-20100317619-A1 | Selective Agents for Pain Suppression | COOK JAMES | 2010-12-16 | — | — | US | disclosed |
| US-20100261711-A1 | SELECTIVE ANTICONVULSANT AGENTS AND THEIR USES | WISYS TECHNOLOGY FOUNDATION (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261711-A1 | SELECTIVE ANTICONVULSANT AGENTS AND THEIR USES | WISYS TECHNOLOGY FOUNDATION (US) | 2010-10-14 | — | — | US | disclosed |
| US-20070049580-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049580-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-7119196-B2 | Anxiolytic agents with reduced sedative and ataxic effects | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| WO-2006004945-A1 | STEREOSPECIFIC ANXIOLYTIC AND ANTICONVULSANT AGENTS WITH REDUCED MUSCLE-RELAXANT, SEDATIVE-HYPNOTIC AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2006-01-12 | — | — | WO | disclosed |
| WO-2006004945-A1 | STEREOSPECIFIC ANXIOLYTIC AND ANTICONVULSANT AGENTS WITH REDUCED MUSCLE-RELAXANT, SEDATIVE-HYPNOTIC AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2006-01-12 | — | — | WO | disclosed |
| US-20060003995-A1 | Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2006-01-05 | — | — | US | disclosed |
| EP-1490344-A2 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | Wisys Technology Foundation, Inc. (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20040082573-A1 | Anxiolytic agents with reduced sedative and ataxic effects | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-04-29 | — | — | US | disclosed |
| WO-2003082832-A2 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003082832-A2 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049580-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | GABRA3, GABRA2, GABRA1 | GABRA3 1/4885GABRG2 14/4885GABRB3 7/4885 |
| US-20100317619-A1 | Selective Agents for Pain Suppression | CNR2, CNR1, OPRL1 | GABRA3 8/4885GABRG2 25/4885GABRB3 7/4885 |
| US-20060003995-A1 | Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects | GABRE, GABRA6, GABRA5 | GABRA3 11/4885GABRG2 21/4885GABRB3 14/4885 |
| US-20040082573-A1 | Anxiolytic agents with reduced sedative and ataxic effects | GABRA3, GABRA2, GABRA1 | GABRA3 1/4885GABRG2 14/4885GABRB3 7/4885 |
| US-20100261711-A1 | SELECTIVE ANTICONVULSANT AGENTS AND THEIR USES | GABRA5, GABRA6, GABRA2 | GABRA3 5/4885GABRG2 11/4885GABRB3 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.